Demonstrating Clinical Utility of Blood Testing

Time: 9:00 am
day: Day Two

Details:

• Genentech’s innovative BFAST trial: Goals, design, and future directions of a blood-only 1L NSCLC trial

• Clinical results from BFAST Cohort A: Blood-identified ALK+ patients treated with alectinib

Speakers: